These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 16469541)
1. Metabolic therapeutics in angina pectoris: history revisited with perhexiline. Inglis S; Stewart S Eur J Cardiovasc Nurs; 2006 Jun; 5(2):175-84. PubMed ID: 16469541 [TBL] [Abstract][Full Text] [Related]
2. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Rupp H; Zarain-Herzberg A; Maisch B Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634 [TBL] [Abstract][Full Text] [Related]
3. Metabolic modulation: a new therapeutic target in treatment of heart failure. Palaniswamy C; Mellana WM; Selvaraj DR; Mohan D Am J Ther; 2011 Nov; 18(6):e197-201. PubMed ID: 20393344 [TBL] [Abstract][Full Text] [Related]
4. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Lee L; Horowitz J; Frenneaux M Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367 [TBL] [Abstract][Full Text] [Related]
5. Calcium channel blockers. Dipalma JR Am Fam Physician; 1983 Feb; 27(2):283-5. PubMed ID: 6829383 [No Abstract] [Full Text] [Related]
11. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Cole PL; Beamer AD; McGowan N; Cantillon CO; Benfell K; Kelly RA; Hartley LH; Smith TW; Antman EM Circulation; 1990 Apr; 81(4):1260-70. PubMed ID: 2180591 [TBL] [Abstract][Full Text] [Related]
12. Metabolic agents in the management of diabetic coronary patients: a new era. Marazzi G; Volterrani M; Rosano GM Int J Cardiol; 2008 Jun; 127(1):124-5. PubMed ID: 18199501 [TBL] [Abstract][Full Text] [Related]
13. Ranolazine: a review of its use in chronic stable angina pectoris. Siddiqui MA; Keam SJ Drugs; 2006; 66(5):693-710. PubMed ID: 16620147 [TBL] [Abstract][Full Text] [Related]
14. The metabolic treatment of patients with coronary artery disease: effects on quality of life and effort angina. César LA; Gowdak LH; Mansur AP Curr Pharm Des; 2009; 15(8):841-9. PubMed ID: 19275648 [TBL] [Abstract][Full Text] [Related]
15. The metabolic treatment of coronary artery disease and heart failure. Di Napoli P Curr Pharm Des; 2009; 15(8):826. PubMed ID: 19275645 [No Abstract] [Full Text] [Related]
16. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA; JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593 [TBL] [Abstract][Full Text] [Related]
17. Spotlight on ranolazine in chronic stable angina pectoris. Siddiqui MA; Keam SJ Am J Cardiovasc Drugs; 2006; 6(5):357-9. PubMed ID: 17083271 [TBL] [Abstract][Full Text] [Related]
18. Ranolazine and other antianginal therapies in the era of the drug-eluting stent. Berger P JAMA; 2004 Jan; 291(3):365-7. PubMed ID: 14734600 [No Abstract] [Full Text] [Related]
19. Chronic angina: new medical options for treatment. McCullough PA Rev Cardiovasc Med; 2005; 6(3):152-61. PubMed ID: 16195688 [TBL] [Abstract][Full Text] [Related]
20. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Killalea SM; Krum H Am J Cardiovasc Drugs; 2001; 1(3):193-204. PubMed ID: 14728034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]